Poll Results Shed Light on Top Bladder, Kidney Cancer Abstracts to Watch at the 2026 Genitourinary Cancers Symposium

With winter giving way to conference season, the 2026 Genitourinary Cancers Symposium (ASCO GU) is underway in San Francisco.

To help capture that excitement, we asked readers to weigh in on some of the biggest bladder cancer and kidney cancer abstracts they’re anticipating from this year’s meeting.

Bladder Cancer

Poll: Which abstracts in bladder cancer are you most looking forward to ahead of ASCO GU?

• Abstract 633: Circulating tumor (ct)DNA-guided adjuvant atezolizumab in MIBC: Exploratory analysis of ctDNA dynamics in the IMvigor011 trial.
• LBA630: Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with MIBC who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
• Abstract 636: Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
• LBA631: RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC

The phase 3 KEYNOTE-B15/EV-304 trial evaluated neoadjuvant and adjuvant enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) vs gemcitabine plus cisplatin in cisplatin-eligible patients with muscle-invasive bladder cancer; it was previously announced that this study met its event-free survival primary end point.

Biomarker-driven care is also front and center in the phase 3 IMvigor011 trial (NCT04660344), which evaluated tumor-informed, minimal residual disease–guided adjuvant atezolizumab (Tecentriq) in patients with circulating tumor DNA (ctDNA)–positive MIBC, with prior reports indicating significantly improved outcomes in ctDNA-positive patients. The upcoming exploratory analyses of ctDNA dynamics may further validate molecular monitoring as a tool for escalation of adjuvant therapy.

Translational insights from the phase 3 NIAGARA trial (NCT03732677) are expected to refine perioperative strategies after the study investigated perioperative durvalumab (Imfinzi) in patients with MIBC.

In patients with advanced urothelial carcinoma, the phase 2 RC48G001 trial (NCT04879329) is evaluating disitamab vedotin (Aidixi) in patients with HER2-expressing, previously treated disease.

On LinkedIn, respondents (n = 24) favored the KEYNOTE-B15 trial (50%), followed by the NIAGARA analysis (25%), the IMvigor011 analysis (21%), and the RC48G001 readout (4%). Results were similar on X (n = 8), with respondents favoring KEYNOTE-B15 (37.5%), followed by IMvigor011 (25%), RC48G001 (25%), and NIAGARA (12.5%).

Kidney Cancer

Poll: Which abstracts in renal cell carcinoma (RCC) are you most looking forward to ahead of ASCO GU?

• LBA418: Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study
• LBA417: Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study
• Abstract 420: Patient-reported outcomes in resected renal cell carcinoma: Active monitoring vs. durvalumab and tremelimumab in the RAMPART trial.
• Abstract 416: CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.

Adjuvant intensification takes center stage in the phase 3 LITESPARK-022 trial (NCT05239728), which compared pembrolizumab (Keytruda) plus belzutifan (Welireg) vs pembrolizumab alone in patients with high-risk, stage II/III and M1 no evidence of disease clear cell RCC following nephrectomy. The trial has met its primary end point of disease-free survival.

In the post–PD-(L)1 metastatic setting, the phase 3 LITESPARK-011 (NCT04586231) compared belzutifan plus lenvatinib (Lenvima) vs cabozantinib (Cabometyx) monotherapy in patients with advanced disease who had previously received an immune checkpoint inhibitor. The study met its primary end point of progression-free survival,

Quality of life is central to the presentation on the phase 3 RAMPART trial (NCT03288532), which compared active monitoring with durvalumab (Imfinzi)-based adjuvant strategies, with or without tremelimumab-actl (Imjudo), in patients with resected RCC. Patient-reported outcomes from this trial may help define when observation is appropriate and when immunotherapy meaningfully improves long-term trajectories.

Finally, the phase 2 CYTOSHRINK (NCT04090710) explored cytoreductive stereotactic hypofractionated radiotherapy combined with ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with metastatic RCC.

Across LinkedIn (100%) and X (62.5%), voters favored LITESPARK-022.